



Deepblue Covid-19 Antigen Lollitest

Laientest / Selbsttest mit CE1434 (1er verpackt)

Omikron-Variante (B.1.1.529, BA.4, BA.5) erkennen geeignet für Kinder ab 0 Jahren alt

| Hersteller | Anhui Deepblue Medical Technology Co.,Ltd. |
|-----------------------|--|
| Rep | Luxus Lebenswelt GmbH |
| CE | CE1434 seit 10.11.2021 |
| BfArM Nummer | AT1288/21 |
| Paul-Ehrlich-Institut | evaluiert |
| EU List | Device #2651 |
| Empfindlichkeit | 98,70% |
| Spezifität | 99,99% |
| Genauigkeit | 99,60% |

| Varianten (SKU) | 1er verpackt |
|-----------------------|------------------|
| Inhalt pro Karton/VPE | 800 St. |
| Abmessungen Karton | 61x54x55cm; 26kg |
| Gebrauchsanleitung | auf Deutsch |





Antigen-Tests auf SARS-CoV-2 zur Eigenanwendung die Gegenstand des Anspruchs nach §1 Satz 1 Coronavirus-Testverordnung (TestV) sind ("Selbsttests")

| Q v de | Q ∨ deep Los Aktionen ∨ | | | | | | | | |
|-----------|---|--------------------|---|---|------|-----------------------|--|--|--|
| | | | | Hersteller | | Europäischer Bevollmä | | | |
| Test-ID | Name des Tests | Evaluierung PEI | Omikron- Erkennung entsprechend der Bridging- Prüfung des PEI | Name ↑= | Land | Name | | | |
| AT1288/21 | COVID-19 (SARS-CoV-2) Antigentestkit (kolloidales Gold) - Speichel | Ja | Ja | ANHUI DEEPBLUE MEDICAL TECHNOLOGY CO.,LTD. | CN | Luxus Lebenswelt GmbH | | | |

Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen

| | W. B. B. | 2.3 | Sensitivity | | | |
|------|--|--|-----------------------------------|------------|-------|----------|
| RDT | Manufacturer | Test name | Cq≤25 | Cq >25-<30 | Cq≥30 | Cq 17-36 |
| Subg | roup of RDT with detection rates of 10 | 0% for Cq ≤25 and of >75% for Cq >25 | i-<30 | | | |
| 54 | Mölaboratory GmbH | mö-screen Corona Antigen Test | 100.0% | 47.8% | 0.0% | 58.0% |
| 4 | Affimedix | TestNOW - COVID-19 Antigen | TestNOW - COVID-19 Antigen 100.0% | | 0.0% | 58.0% |
| 55 | MP Biomedicals Germany GmbH | Rapid SARS-CoV-2 Antigen Test Card | 100.0% | 43.5% | 0.0% | 54.0% |
| 68 | Qingdao Hightop Biotech Co., Ltd. | Hightop SARS-CoV-2 (Covid-19) Antigen Rapid Test | 100.0% | 43.5% | 0.0% | 54.0% |
| 92 | Xiamen Boson Biotech Co., Ltd | SARS-CoV-2 Antigen Schnelltest | 100.0% | 43.5% | 0.0% | 54.0% |
| 27 | DNA Diagnostic A/S. | Covid-19 Antigen Detection Kit | 100.0% | 39.1% | 10.0% | 54.0% |
| 9 | Anhui Deepblue Medical Technology Co., Ltd. | COVID-19 (SARS CoV-2) Antigen Test Kit (Colloidal Gold) | 100.0% | 39.1% | 0.0% | 52.0% |
| 28 | Edinburgh Genetics Limited | Edinburgh Genetics ActivXpress + | 100.0% | 34.8% | 0.0% | 50.0% |



ANHUI DEEPBLUE MEDICAL TECHNOLOGY CO.,LTD.

Website: http://www.dbluemedical.com/
Address: 4th Floor D-1# Zone, Pearl Industrial Park 106 Innovation Avenue, High-Tech Development Zone 230088 Hefei, Anhui, China

Statement

We, Anhui Deepblue Medical Technology Co., Ltd located at 4th Floor, D-1# Zone, Pearl Industrial Park, 106 Innovation Avenue, High-Tech Development Zone, 230088 Hefei, Anhui, China are here by to declare: As the manufacture of the product:

COVID-19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold)
COVID-19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold) - Saliva
COVID-19 (SARS-CoV-2) Antigen Test Midstream — Saliva
Would like to declare that the products are mainly use two antibody raw materials, the names and details are listed as follows:

| No. | Material Name | Cat. | Material performance |
|-----|---------------------------------|------|------------------------------------|
| 1 | 2019-nCoV Nucleocapsid Antibody | | Concentration>1.0mg/mL, purity>90% |
| 2 | 2019-nCoV Nucleocapsid Antibody | | Concentration>1.0mg/mL, purity>90% |

The COVID-19 antigen test kits produced by our company have been verified by in-silico analysis and related experiments. The results showed that our product can effectively detect the following mutant strains (including but not limited to) without performance changes:

| Variant | Pango lineage | Emergence | | |
|---------|---------------|--------------|--|--|
| Alpha | B.I.1.7 | UK | | |
| Beta | B.1.351 | South Africa | | |
| Delta | B.I.617.2 | India | | |
| Карра | B.I.617.1 | India | | |





ANHUI DEEPBLUE MEDICAL TECHNOLOGY CO.,LTD.

Website:http://www.dbluemedical.com/

Address: 4th Floor D-1# Zone, Pearl Industrial Park 106 Innovation Avenue, High-Tech Development Zone 230088 Hefei, Anhui, China

| Gamma | P.I | Brazil |
|---------|---------|--------------------|
| Zeta | P.2 | Brazil |
| Lambda | C.37 | Peru |
| lota | B.1.526 | USA |
| Eta | B.1.525 | Multiple countries |
| Mu | B.1.621 | Columbia |
| Omicron | BA.I | USA |
| Omicron | BA.2 | UK |
| Omicron | XE | UK |
| Omicron | BA.4 | UK、South Africa |
| Omicron | BA.5 | South Africa |

Our company will continue to pay attention to the mutation of the novel coronavirus, and will continue to track the detection of the mutant strain of the novel coronavirus. The relevant information will be updated and announced timely.

All rights are reserved by Anhui Deepblue Medical Technology Co., Ltd. Company name: Anhui Deepblue Medical Technology Co., Ltd.

Date: May 24, 2022

Stamp



EC Certificate No. 1434-IVDD-484/2021

EC Design-examination
Directive 98/79/EC concerning
in vitro diagnostic medical devices

Polish Centre for Testing and Certification certifies that manufactured by:

Anhui Deepblue Medical Technology Co., Ltd. 4th Floor, D-1#Zone, Pearl Industrial Park, 106 Innovation Avenue, High-Tech Development Zone, 230088 Hefei, Anhui, China

in vitro diagnostic medical devices for self-testing

COVID-19 (SARS-CoV-2) Antigen Test Kit

(Colloidal Gold) - Saliva

The list of medical devices covered by this certificate is provided in the annex 1

in terms of design documentation, comply with requirements of Annex III (Section 6) to Directive 98/79/EC (as amended) implemented into Polish law, as evidenced by the audit conducted by the PCBC

Validity of the Certificate: from 10.11.2021 to 27.05.2024

The date of issue of the Certificate: 10.11.2021

The date of the first issue of the Certificate: 10.11.2021

C E 1434

Issued under the Contract No. MD-113/2021 Application No: 230/2021 Certificate bears the qualified signature. Warsaw, 10.11.2021 Module A1 Anna Elektron podpisa Anna Małgorzata Wyroba Data: 20 16:15:24

Elektronicznie podpisany przez Anna Małgorzata Wyroba Data: 2021.11.10 16:15:24 +01'00'

Vice-President



ANNEX TO THE CERTIFICATE

VALID ONLY WITH CERTIFICATE No 1434-IVDD-484/2021

List of medical devices covered by the certificate:

DEEPBLUE, ShenLanTest, Highbluetest, NewBluetest, Quicklyblue

REF: SL030101SST-1, SL030101SST-2, SL030101SST-3, SL030101SST-4, SL030101SST-5, SL030101SST-6, SL030101SST-7, SL030101SST-8, SL030101SST-9, SL030101SST-10, SL030101SST-11, SL030101SST-12, SL030101SST-13, SL030101SST-14, SL030101SST-15, SL030101SST-16, SL030101SST-17, SL030101SST-18, SL030101SST-19, SL030101SST-20, SL030101SST-21, SL030101SST-22, SL030101SST-23, SL030101SST-24, SL030101SST-25



Issued under the Contract No. MD-113/2021 Application No: 230/2021 Certificate bears the qualified signature. Warsaw, 10/11/2021 Anna Elektronicznie podpisany przez Anna Małgorzata Wyroba Data: 2021.11.10 16:16:26 +01'00' Vice-President

ANHUI DEEPBLUE MEDICAL TECHNOLOGY CO.,LTD.



Website:http://www.dbluemedical.com/

Address:4th Floor D-1# Zone, Pearl Industrial Park 106 Innovation Avenue, High-Tech Development Zone 230088 Hefei, Anhui, China

Statement

With the development of the pandemic, new variants of the SARS-CoV-2 have been reported all over the world.

For the effective control of the pandemic, rapid and accurate screening of the target SARS-CoV-2 including the new occurred variants is of great significance.

Currently, the new variant, which is defined as Omicron (B.1.1.529), has been found in South Africa.

The variant sites of B.1.1.529 located main in the Spike proteins of SARS-CoV-2. According to the research, among the 50 variant sites, there are more than 30 variant sites located in the Spike protein, which induce 43 amino acid mutated residues in the Spike protein. Meanwhile, there are also some variant sites to the N protein. And these variant sites in N protein are not in the critical sites.

The detection target of the DEEPBLUE COVID-19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold) is the N protein of SARS-CoV-2. The recognition site of our Antigen Test Kit locates in the site 45-187 of N protein. The new occurred variant Omicron of SARS-CoV-2 will not affect the screen results of the kit. The detection performance of our COVID-19 (SARS-CoV-2) Antigen Test Kit including the sensitivity and specificity can be well guaranteed. And we will also continue pay attention to the variants of the SARS-CoV-2 and make the update on the website.

Anhui DeepBlue Medical Technology Co. Ltd. 30/11/2021

So/11/201 安徽深蓝医疗科技股份有限公司 ANHUI DEEPBLUE MEDICAL TECHNOLOGY CO.,LTD.



www.dbluemedical.com

DECLARATION OF CONFORMITY

MANUFACTURER: ANHUI DEEPBLUE MEDICAL TECHNOLOGY CO.,LTD.

4th Floor, D-1# Zone, Pearl Industrial Park, 106 Innovation Avenue,

High-Tech Development Zone, 230088 Hefei, Anhui, People's

Republic of China

EUROPEAN Luxus Lebenswelt GmbH

REPRESENTATIVE: Kochstr. 1, 47877, Willich, Germany

PRODUCT: COVID-19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold) -Saliva

Models: SEE ATTACHMENT

REF: SEE ATTACHMENT

CLASSIFICATION: SELF-TESTING

EDMA CODE: 15 70 90 90 00

CONFORMITY ASSESSMENT ROUTE: Following the procedure relating to the EC Declaration of Conformity set out in Annex III Section 6 of Directive 98/79/EC.

WE HEREWITH DECLARE THAT THE ABOVE MENTIONED PRODUCTS MEET THE PROVISIONS OF THE COUNCIL DIRECTIVE 98/79/EC. ALL SUPPORTING DOCUMENTATION IS RETAINED UNDER THE PREMISES OF THE MANUFACTURER.

THE MANUFACTURER IS EXCLUSIVELY RESPONSIBLE FOR THE DECLARATION OF CONFORMITY.

STANDARDS APPLIED: EN ISO 13485:2016

EN ISO 18113-1:2011, EN ISO 18113-4:2011, EN 13612: 2002/AC:2002, EN ISO 23640:2015, EN 13641: 2002, EN ISO 15223-1: 2016, EN 13975:2003, EN 13532:2002, EN ISO

14971:2012.

NOTIFIED BODY: Polish Center for Testing and Certification

469 Puławska Street,02-844 Warsaw,Poland

(EN) CERTIFICATE(S): 1434-IVDD-484/2021

START OF CE-MARKING: 2021-11-10

SIGNATURE:

PLACE, DATE OF ISSUE: HEFEI, 2021-11-12

CHEN FENGLING

GENERAL MANAGER

013101EC Declaration of Conformity

DOC-COVID-19 Ag(M/0)







Product Service

Certificate

No. Q5 003706 0001 Rev. 01

Holder of Certificate: ANHUI DEEPBLUE MEDICAL

TECHNOLOGY CO.,LTD.

4th Floor, D-1# Zone Pearl Industrial Park

106 Innovation Avenue, High-Tech Development Zone

230088 Hefei, Anhui

PEOPLE'S REPUBLIC OF CHINA

Certification Mark:



Scope of Certificate: Design and Development, Production and Distribution of

In Vitro Diagnostic Reagents by Colloidal Gold and Enzyme Chemical Reaction Method, Medical Ultrasonic Couplant, Acetowhite Solution, Epithelial Tissue Staining Solution, Rapid Test for Vaginitis(Polyamines) and Cell Preservation

Solution

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: www.tuvsud.com/ps-cert?q=cert:Q5 003706 0001 Rev. 01

Report No.: SH21130301

 Valid from:
 2021-06-22

 Valid until:
 2024-06-21

Date, 2021-06-16 Christoph Dicks

Head of Certification/Notified Body







Certificate

No. Q5 003706 0001 Rev. 01

Applied Standard(s): EN ISO 13485:2016

Medical devices - Quality management systems -

Requirements for regulatory purposes

(ISO 13485:2016) DIN EN ISO 13485:2016

ANHUI DEEPBLUE MEDICAL TECHNOLOGY CO.,LTD. Facility(ies):

4th Floor, D-1# Zone, Pearl Industrial Park, 106 Innovation Avenue, High-Tech Development Zone, 230088 Hefei, Anhui,

PEOPLE'S REPUBLIC OF CHINA

See Scope of Certificate

TÜV®



COVID-19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold) - Saliva

For self-testing. For in vitro diagnostic use only. Please read the instruction carefully before use.




[Intended use]


This product is used for in vitro qualitative detection of the SARS-CoV-2 antigen in human saliva specimen. This product is intended for home self-testing as a rapid test for novel coronavirus infection. Both symptomatic and asymptomatic infections can be tested. The final diagnosis should be made by medical staff based on laboratory results and symptom analysis. This product is suitable for users over 10 years old. Users under 10 years old are advised to complete the self-test under the guidance and assistance of appropriate family members.

[Materials and Components]





[Test Procedure]



Open the package and take out the test device. Know the observation window and specimen well(S).It should be used within one hour.

Unscrew the cap of the extraction tube counterclockwise

Press the pre-drilled circle, make a hole in the outer box, and then insert the bottom of the antigen extraction tube into the hole.

Remove the sterilized swab from the packaging.

[Summary]

The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection, asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main Manifestations include fever, fatigue and dry cough. Diarrhea is a very common symptom in mostly 3 to 7 days. The main standard management of the condition and some serious complications may occur. If without prompt treatment it may even lead to death.

[Test principle] This product uses the double antibody sandwich method to detect the SARS-CoV-2 N protein. When the sample contains the coronavirus antigen, both the test line (C) and the control line (T) will appear, and the result will be positive. When the sample does not contain the coronavirus antigen or no coronavirus antigen is detected, the test line (T) will not appear, only control line (C) will appear.

[Limitations of inspection methods]

- 1. This test kit is only used for in vitro diagnosis.

 2. This test kit is only used for in vitro diagnosis.

 2. This test kit is only used for in vitro diagnosis.

 3. This test kit is only used for qualitative detection and cannot indicate the level of SARS-CoV-2 antigen in the specimen.

 4. This test kit is only a clinical auxiliary diagnostic tool. If the result is positive, it is recommended to use other methods for further examination in time and the doctor's diagnosis shall prevail.

 5. This test does not determine the actiology of the respiratory infection caused by micro-organisms other than the SARS-CoV-2 vitrus.
- 6. This test can detect both the viable and the non-viable SARS-CoV-2 virus, the accuracy of the test depends on the quality of
- 6. This test can detect both the viable and the non-viable SAKS-CoV-2 virus, the accuracy of the test depends on me quanty of the swab sample-false negative results may be given following poor sampling.

 7. Any failure to respect the test procedure may negatively impact the performance of the test and/or invalidate the test result.

 8.If the result of the test is negative, yet clinical symptoms persist, it is advised that you carry out additional tests using other clinical methods. A negative result at no time rules out the presence of antigens of the SARS-CoV-2 virus in the sample, as they may be present but at a level inferior to the minimum detection level of the test, or if the sample has been collected incorrectly.

 9.A negative result does not rule out infection by the SARS-CoV-2 virus, particularly in people who have come into contact with
- the virus. Follow-up tests with molecular diagnostics should be scheduled to rule out infection in these people. Persons who show symptoms of the disease but have a negative result until infection is ruled out should follow country-specific restrictions.

 10. This test is not a substitute for a medical consultation, or for the result of a biological analysis carried out in a medical analysis laboratory.

 11. Positive test results do not exclude the possibility of co-infections of other pathogens

[Warnings and Precautions]

- Read the instructions carefully before using the kit, and strictly control the reaction time. If you do not follow the instructions, ou will get inaccurate results.
- Do not eat, drink, chew gum, smoke or vape for at least 30 minutes before collecting saliva. False negative results can occur if the saliva is not collected properly.
- 3. Guard against moisture, do not open the aluminum platinum bag before it is ready for testing. Do not use it if the aluminum

- Guard against moisture, do not open the aluminum platinum bag before it is ready for testing. Do not use it if the aluminum foil bag is damaged or the test device is damp.
 Please use it within the validity period.
 Do not replace the components in this kit with components in other kits.
 Do not fullet the specimen when testing, otherwise you may get inaccurate results.
 The kit shall be stored in strict accordance with the conditions specified in this manual. Please do not store the kit under functions are the strict accordance with the conditions. freezing conditions.
- 8. The test methods and results must be interpreted in strict accordance with this specification
- 9. Negative results may occur if the SARS-CoV-2 antigen titer in the specimen falls below the minimum detection limit of this

In II. If the extraction reagent is individual packing and one piece per test device, the batch number, expiration date and other information cannot be marked separately due to the space is limited, but those information will be consistent with the

- corresponding test kit.

 11. There is no reduction in sensitivity in the Deepblue Antigen test against the UK variant, Brazilian variant or the South African
- 12. Do not swallow the extraction reagent. If accidentally touch the human skin, eyes or mucous membranes, please rinse with water immediately. If discomfort occurs, please consult a doctor.

[Storage conditions & period of validity]

1. Store at 4°C~30°C, and it is valid for 24 mon



Insert the soft tip of sterilized swab into the mouth, actively swab inside of the mouth and tongue to collect saliva for approximately 30-60s until the soft tip is filled with saliva.



Unscrew the small white cap on the top of the extraction tube.



Put the swab specimen into the extraction tube, rotate the swab for about 10 seconds, and press the swab head against the tube wall 3 times to release the antigen in the swab.



Hold the extraction tube vertically and add two drops of the test specimens into the specimen well

o o o



Tighten the cap of the extraction tube clockwise.



10

Read result at 15 minutes Do not read results after 30 minutes



Please put all used materials in the enclosed collection bag for proper disposal. The test kit can be disposed of with normal household waste in compliance with the applicable local regulations.

[Interpretation of test results]

Negative result:



If there is only a control line (C) and the test line (T) is colorless, it indicates that SARS-CoV-2 antigen has not been detected and the result is negative annigen has not occurred and not leave its negative. If the test result is negative: Continue to comply with all applicable rules regarding contacts and protective measures. Even if the test is negative, there may be an infection. In case of doubt, repeat the test after 1-2 days because the coronavirus cannot be accurately detected at all stages of infection, and there is a possibility of false negatives for negative results.

Positive result:



If both the control line (C) and the test line (T) appear, it indicates that SARS-CoV-2 antigen has been detected and the result is positive.

If the test result is positive:

Currently, there is a suspected infection of COVID-19.

Contact your doctor or local health department immediately.

- Comply with local regulations, self-isolate and report according to local regulations. Perform PCR test for confirmation.



If the control line (C) is not observed, the test is considered to be invalid whether the test line (T) is visible or not. A new test needs to be performed using a new test device.

If the test result is invalid, it may be caused by incorrect test operation. Please repeat the test.

If the test result is still invalid, please contact your doctor or COVID-19 testing center.

After the aluminum foil bag is unscaled, the test device should be used as soon as possible and within one hour (15 ~ 30°C, Humidity ≤80%).

[Sample Transport and Storage] Freshly collected specimens should be processed as soon as possible. It should be no later than one hour after collection.

[Quality Control]

Program control is included in the test, A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient volume of the specimen

[Performance index]

- 1. Limit of detection (LOD): TCID-0/mL is 80. This means that if the virus concentration in the body does not exceed this
- 1. Limit of detection (LOD): 1-L15g/mL is 80. This means that it the virus concentration in the test result will be negative.

 2. High Dose Hook Effect: When the virus concentration exceeds 1.4 x 10⁵ TCID₅₀/mL, the result may be false negative.

 3. Cross-reactivity: There is no cross-reactivity, including human coronavirus DC3, human coronavirus NLG3, human coronavirus HKUI, MERS-coronavirus, SARS coronavirus, adenovirus 3, and parainfluenza virus type 2, Enterovirus, respiratory syncytial virus (A), parainfluenza virus type 3, parainfluenza virus type 44, influenza A H3N2 (Wisconsin 67/05), influenza A H1N1, influenza B (VICRTORIA), Rhinovirus (HRVA30), Haemophilus influenza (Strentoscorous propense). Candida albiman Bacillus nettusis. Mycoolasma memoniae.
- H3N2 (Wisconsin/67/05), influenza A H1N1, influenza B (VICRTORIA), Rhinovirus (HRVA30), Haemophilus influenzae, Streptococcus projenococus progenes, Candida albicans, Bacillus pertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumonia, Mycobacterium tuberculosis, Pneumocystis, Pseudomonas Bacteria, human pneumonia virus (hMPV), parainfluenza virus type 1, Staphylococcus epidermidis, Streptococcus salivarius, etc.

 4. Microbial Interference Studies: There is no interference in studies on the following microorganisms or pathogens, including parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, parainfluenza virus type 4a, adenovirus, human pneumonia virus (hMPV), A H3N2 Influenza (Wisconsin/67/05), H1N1 influenza, Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus progenes, influenza B (Malaysia 2506/04), enterovirus, respiratory syncytial virus, Rhinovirus, Chlamydia pneumoniae, Legionella pneumoniae, Mycobacterium tuberculosis, Pneumocystis, Pseudomonas, Candida albicans, Bacillus pertussis, Mycoplasma pneumoniae, Staphylococcus epidemidis, Streptococcus salivarius, human coronavirus 229E, human coronavirus OC43, human coronavirus NL63, human coronavirus HKU1, MERS coronavirus, etc.

 5. Endogenous Interference Studies: There is no interference in studies on the following substances, including blood, mucin, Alkalol, dexamethasone, Neilmed, benzocaine, oseltamivir, tobramycin, mupirocin, biotin, etc.

[Clinical Performance]

The overall study scale was 600 cases, 150 positive samples and 450 negative samples.

Statistics of test results of saliva samples:

| | Reference RT-PCR Assay | | | | | | 95% Wilso | n Score CI | |
|---|------------------------|-------|-----|-----|-------|-----|-----------|------------|--------|
| Г | | | | | | | | LCI | UCI |
| Г | DEEP | | POS | NEG | TOTAL | PPA | 98.7% | 92.33% | 99.07% |
| | BLUE | POS | 148 | 0 | 148 | NPA | >99.9% | 98.17% | 100% |
| | SARS- CoV-2 | NEG | 2 | 450 | 452 | PPV | >99.9% | 98.17% | 100% |
| | Ag Test | TOTAL | 150 | 450 | 600 | NPV | 99.6% | 92.76% | 99.31% |

Sensitivity: 98.7% (95% CI: 92.33% - 99.07%) Specificity: >99.9% (95% CI: 98.17% - 100%) Sensitivity: Compared with the RT-PCR Assay, a

among people infected with SARS-CoV-2 virus, the probability of correct detection by the DeepBlue SARS-CoV-2 Ag Test Kit.

Specificity: Compared with the RT-PCR Assay, among people who have not been infected with SARS-CoV-2 virus, the probability of correct detection by the DeepBlue SARS-CoV-2 Ag Test Kit.

[Index of Symbols]

| IVD | The product is used in vitro | 2 | Do not re-use | 誉 | Avoid excessive exposure to the sun |
|-------------|--|---|---|----------|---|
| Β | Expire date | | Please read the instruction for use carefully before using | سا | Date of manufacture |
| \triangle | Warning, please refer to the instructions in the package | | Manufacturer | ® | Don't use the product when the package is damaged |

| 47C | Temperature range of product storage | LOT | Batch number | \sum_ | Contain sufficient quantity for <n> tests</n> |
|--------|---|--------------|--------------|----------------------------|--|
| EC REP | European union authorization representative | * | Keep dry | C € ₁₄₃₄ | CE Mark |



ANHUI DEEPBLUE MEDICAL TECHNOLOGY CO., LTD.
4th Floor,D-1# Zone, Pearl Industrial Park, 106 Innovation Avenue,
High-Tech Development Zone,230088 Hefei, Anhui, China.
LUXUS LEBENSWELT GMBH
Koehstr. 1, 47877, Willich, Germany

EC REP

Lotus Global Co Ltd
23 Maine Street, Reading, RG2 6AG, England, United Kingdom.
E-mail:peter@lotusglobaluk.com
Shenzhen KangDaAn Biological Technology co.,LTD.
East-1, 3rd floor, Building 2, Shunheda factory, Liuxiandong industrial
zone, Xili street, Nanshan district, Shenzhen China.
Goodwood Medical Care Ltd.
1-2Floor,3-919 Yongzheng Street Jinzhou Districet,Dalian,China. UK Responsible Person

Swab Information